Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human antibodies by design

T J Vaughan1, J K Osbourn, P R Tempest

  • 1Cambridge Antibody Technology, Melbourn, Cambridgeshire, UK. tris.vaughan@camb-antibody.co.uk

Nature Biotechnology
|June 13, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An integrated mechanical degradation model to explore the mechanical response of a bioresorbable polymeric scaffold.

Journal of the mechanical behavior of biomedical materials·2024
Same author

Bone cell mechanosensation of fluid flow stimulation: a fluid-structure interaction model characterising the role integrin attachments and primary cilia.

Biomechanics and modeling in mechanobiology·2014
Same author

Multiscale modeling of trabecular bone marrow: understanding the micromechanical environment of mesenchymal stem cells during osteoporosis.

Journal of biomechanical engineering·2014
Same author

Cell morphology and focal adhesion location alters internal cell stress.

Journal of the Royal Society, Interface·2014
Same author

A fluid-structure interaction model to characterize bone cell stimulation in parallel-plate flow chamber systems.

Journal of the Royal Society, Interface·2013
Same author

A three-scale finite element investigation into the effects of tissue mineralisation and lamellar organisation in human cortical and trabecular bone.

Journal of the mechanical behavior of biomedical materials·2012
Same journal

Unlocking the chemical potential of filamentous fungi using prime editing.

Nature biotechnology·2026
Same journal

A genome-scale CRISPRi perturbation atlas of human induced pluripotent stem cells.

Nature biotechnology·2026
Same journal

Prime editing for precise genome engineering and modulation of fungal metabolism.

Nature biotechnology·2026
Same journal

Retargeted serine integrases for one-step, precise integration of large DNA sequences in human cells.

Nature biotechnology·2026
Same journal

A retargeted recombinase for precise insertion of large DNA.

Nature biotechnology·2026
Same journal

Experiment-guided AlphaFold3 resolves measurement-consistent protein ensembles.

Nature biotechnology·2026
See all related articles

Fully human monoclonal antibodies (mAbs) are crucial for effective therapy, overcoming immune rejection seen with rodent-derived versions. Advances in phage display and transgenic mice are enabling the production of these advanced therapeutic antibodies.

Area of Science:

  • Biotechnology
  • Immunology
  • Pharmacology

Background:

  • Monoclonal antibodies (mAbs) are valuable therapeutics due to their natural role and low toxicity.
  • Rodent-derived mAbs face limitations in clinical use because of patient immune responses.
  • Chimerized and humanized mAbs represent progress, but fully human antibodies are the next frontier.

Purpose of the Study:

  • To discuss the development and potential of fully human monoclonal antibodies.
  • To highlight advancements in generating human mAbs for therapeutic applications.

Main Methods:

  • Phage display technology for generating human antibody libraries.
  • Transgenic mouse models for producing human antibodies.
  • Clinical trials of fully human mAbs from phage display.

Related Experiment Videos

Main Results:

  • Fully human mAbs are now producible through phage display and transgenic mice.
  • Phage display-derived fully human mAbs have entered clinical trials.
  • These technological advances are paving the way for the full therapeutic potential of antibodies.

Conclusions:

  • The development of fully human monoclonal antibodies is essential for overcoming immunogenicity issues.
  • Phage display and transgenic mouse technologies are key to producing safe and effective human mAbs.
  • These advancements promise to unlock the complete therapeutic potential of antibody-based treatments.